Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced successful mapping of the ...

The medicines regulator has flagged up a small increased risk of Guillain-Barré syndrome after RSV vaccination in adults over ...

As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness and proper prevention crucial. Recognising this urgent public health concern ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention (CDC). This marks ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.